Upgrade to SI Premium - Free Trial

BMO Capital Reiterates Outperform Rating on Alnylam (ALNY), Sees Significant Upside Following Data

June 24, 2024 7:52 AM
BMO Capital analyst Kostas Biliouris reiterated an Outperform rating and $234.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY). Earlier Alnylam ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Hot Comments

Next Articles